Susana Campos, MD
Medical Oncology · Boston, MANPI 1912966052
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $190,239 of the $227,451 with a category attached, or 83.6%. It is spread thinly across 19 manufacturers, the largest accounting for just 20.2%. 2025 is the largest year on record at $55,934, 2.4 times the $23,737 reported in 2019. Among medical oncology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 192 payments — averaging $1184.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$46K
- AstraZeneca$41K
- GSK$32K
- Genmab U.S., Inc.$26K
- Merck Healthcare Kgaa$17K
- Merck$15K
- plus $50K from 13 others
Across 95 payments — averaging $11,708 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$530K
- Tesaro, Inc.$364K
- Pfizer$95K
- Genmab U.S., Inc.$81K
- Seagen Inc.$36K
- Merck$5K
- plus $686 from 1 others
What the payments were for
- Consulting fees$190,23984%
- Speaking & faculty fees$8,0584%
- Travel & lodging$25,79511%
- Food & beverage$3,3151%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 52 | $45,998 |
| AstraZeneca | 29 | $41,357 |
| GSK | 20 | $31,592 |
| Genmab U.S., Inc. | 31 | $25,742 |
| Merck Healthcare Kgaa | 6 | $17,067 |
| Merck | 6 | $15,395 |
| Immunogen, Inc. | 6 | $10,687 |
| Pfizer | 8 | $9,409 |
| EMD Serono Research & Development Institute, Inc. | 1 | $8,172 |
| Seagen Inc. | 5 | $5,160 |
| Tesaro, Inc. | 7 | $4,334 |
| AbbVie | 2 | $2,981 |
| EMD Serono, Inc. | 1 | $2,700 |
| Novartis | 1 | $2,293 |
| Clovis Oncology, Inc. | 5 | $1,670 |
| Daiichi Sankyo Inc. | 1 | $1,290 |
| Corcept Therapeutics | 5 | $776 |
| E.r. Squibb & Sons, L.L.C. | 1 | $650 |
| Taiho Oncology, Inc. | 5 | $178 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$227,451 in reported general payments places this provider in the 90th percentile of 308 medical oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 15 | $473 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Boston
- George DemetriBoston$1.6M
- Keith FlahertyBoston$932K
- Alicia MorgansBoston$690K
- Pasi Antero JanneBoston$458K
- Robert HaddadBoston$451K
- Irene GhobrialBoston$431K
- Joaquin Bellmunt MolinsBoston$415K
- Jeremy AbramsonBoston$334K
- Justin GainorBoston$324K
- Narjust FlorezBoston$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.